CTLA-4 inhibitors are mostly correlated with the possibility of developing hypothyroidism, while PD-1/PD-L1 inhibitors can lead to thyrotoxicosis and hypothyroidism [19]. This evidence concerns the gene PDCD1 and hypothyroidism.